The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.
 
Jonathan W. Friedberg
Consulting or Advisory Role - Bayer
Research Funding - Kite, a Gilead company (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Roche
 
Andres Forero-Torres
Speakers' Bureau - Seagen
Research Funding - Daiichi Sankyo (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Novartis (Inst); Oncothyreon (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst); TRACON Pharma (Inst)
 
Beata Holkova
Research Funding - Seagen
 
Jerome H. Goldschmidt
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Genentech; Roche
Research Funding - Genentech; Roche; Seagen
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Genentech; Roche
 
Ralph V. Boccia
Consulting or Advisory Role - Celgene; Onyx
Speakers' Bureau - Amgen; Celgene; Eisai; Incyte; Onyx; Seagen
Research Funding - Seagen
Travel, Accommodations, Expenses - Amgen; Celgene; Eisai; Incyte; Onyx; Seagen
 
Rodolfo Bordoni
Employment - GCS; NHCI
Speakers' Bureau - Biogen; Bristol-Myers Squibb; Genentech; Pfizer; Roche
Research Funding - Seagen
 
Vivian Jean M. Cline
Research Funding - Seagen
 
Dipti Patel-Donnelly
No Relationships to Disclose
 
Patrick J. Flynn
Employment - ARIAD (I); Sanofi (I)
Stock and Other Ownership Interests - ARIAD (I)
Speakers' Bureau - Celgene; Lilly; Novartis; Teva
 
Gregg A. Olsen
Research Funding - Seagen
 
Robert W. Chen
Honoraria - Genentech/Roche; Merck; Millennium; Seagen
Consulting or Advisory Role - Genentech/Roche; Merck; Seagen
Speakers' Bureau - Genentech/Roche; Millennium; Seagen
Research Funding - Millennium (Inst); Pharmacyclics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck; Seagen
 
Faith Galderisi
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Yinghui Wang
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Jeff Porter Sharman
Leadership - US Oncology
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; TG Therapeutics
Speakers' Bureau - Gilead Sciences
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
Expert Testimony - Gilead Sciences
 
Christopher A. Yasenchak
Research Funding - Seagen